New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials

Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy

(2011) Eric Lawitz et al.   ANTIVIRAL RESEARCH

OC-13 ADVANCE study: Final results of the phase III trial with telaprevir in combination with PEG-IFN and RBV in treatment-naïve genotype 1 HCV

(2011) M. Rizzetto et al.   DIGESTIVE AND LIVER DISEASE

1373 FIRST REPORT OF SVR12 FOR A NS5A REPLICATION COMPLEX INHIBITOR BMS-790052 IN COMBINATION WITH PEG-IFNa-2A AND RBV: PHASE 2A TRIAL IN TREATMENT-NAIVE HCV-GENOTYPE-1 SUBJECTS

(2011) S. Pol et al.   JOURNAL OF HEPATOLOGY

425 FOUR-WEEK TREATMENT WITH GS-9256 AND TEGOBUVIR (GS-9190), ± RBV ± PEG, RESULTS IN ENHANCED VIRAL SUPPRESSION ON FOLLOW-UP PEG/RBV THERAPY, IN GENOTYPI 1A/1B HCV PATIENTS

(2011) G.R. Foster et al.   JOURNAL OF HEPATOLOGY

1218 HIGH SUSTAINED VIROLOGICAL RESPONSE (SVR) RATE AFTER DANOPREVIR FOR ONLY 14 DAYS ASSOCIATED WITH PEG-INTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE CHRONIC HCV GENOTYPE 1 PATIENTS

(2011) P. Larrey et al.   JOURNAL OF HEPATOLOGY

468 UNIQUE PATTERN OF VIROLOGIC RESPONSE IN PATIENTS WITH GENOTYPE-1 HCV: A PHASE II STUDY OF CTS-1027 IN COMBINATION WITH PEGINTERFERON/RIBAVIRIN (SOC) IN NULL RESPONDERS

(2011) M. Rodriguez-Torres et al.   JOURNAL OF HEPATOLOGY

410 24-WEEK TREATMENT WITH CTS-1027 IN COMBINATION WITH RIBAVIRIN REDUCES HCV-RNA IN TREATMENT NAIVE GENOTYPE-1 PATIENTS

(2011) M. Chojkier et al.   JOURNAL OF HEPATOLOGY

458 FINAL RESULTS OF THE PHARMACOKINETICS, EFFICACY, AND SAFETY/TOLERABILITY OF 400 AND 600 MG ONCE-DAILY DOSING OF ACH-1625 (HCV NS3 PROTEASE INHIBITOR) IN HCV GENOTYPE 1

(2011) V. Detishin et al.   JOURNAL OF HEPATOLOGY

1376 THE ASPIRE TRIAL: TMC435 IN TREATMENT-EXPERIENCED PATIENTS WITH GENOTYPE-1 HCV INFECTION WHO HAVE FAILED PREVIOUS PEGIFN/RBV TREATMENT

(2011) S. Zeuzem et al.   JOURNAL OF HEPATOLOGY

1237 NO RESISTANCE TO IDX184 WAS DETECTED IN 3-DAY AND 14-DAY CLINICAL STUDIES OF IDX184 IN GENOTYPE 1-INFECTED HCV SUBJECTS

(2011) J.F. McCarville et al.   JOURNAL OF HEPATOLOGY

444 SVR FOR CONTROLLED-RELEASE INTERFERON ALPHA-2B (CR2B) +RIBAVIRIN COMPARED TO PEGYLATED INTERFERON ALPHA-2B (PEG2B) +RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 (G1) HEPATITIS C: FINAL RESULTS FROM SELECT-2

(2011) E. Lawitz et al.   JOURNAL OF HEPATOLOGY

1220 ABT-450/RITONAVIR (ABT-450/R) COMBINED WITH PEGYLATED INTERFERON ALPHA-2A AND RIBAVIRIN (SOC) AFTER 3-DAY MONOTHERAPY IN GENOTYPE 1 HCV-INFECTED TREATMENT-NAIVE SUBJECTS: 12-WEEK INTERIM EFFICACY AND SAFETY RESULTS

(2011) E. Lawitz et al.   JOURNAL OF HEPATOLOGY

1195 BMS-650032, AN NS3 INHIBITOR, IN COMBINATION WITH PEGINTERFERON ALPHA-2A AND RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION

(2011) J.-P. Bronowicki et al.   JOURNAL OF HEPATOLOGY

1224 FACTORS AFFECTING HCV VIRAL LOAD RESPONSE TO THE NON-NUCLEOSIDE POLYMERASE INHIBITORS ABT-072 AND ABT-333

(2011) T. Middleton et al.   JOURNAL OF HEPATOLOGY

Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

(2011) Bruce R. Bacon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-α in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 2 or 3

(2010) David R. Nelson et al.   GASTROENTEROLOGY

Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia and Decrease the Need for Ribavirin Dose Reduction

(2010) Alexander J. Thompson et al.   GASTROENTEROLOGY

IL28B and the Control of Hepatitis C Virus Infection

(2010) Ashwin Balagopal et al.   GASTROENTEROLOGY

S-Adenosyl Methionine Improves Early Viral Responses and Interferon-Stimulated Gene Induction in Hepatitis C Nonresponders

(2010) Jordan J. Feld et al.   GASTROENTEROLOGY

Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy

(2010) Stephen A. Harrison et al.   HEPATOLOGY

Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C

(2010) Fred Poordad et al.   HEPATOLOGY

Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients

(2010) Joep de Bruijne et al.   HEPATOLOGY

2005 VIROLOGIC RESPONSE RATES FOLLOWING 4 WEEKS OF FILIBUVIR IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONICALLY-INFECTED HCV GENOTYPE-1 PATIENTS

(2010) I. Jacobson et al.   JOURNAL OF HEPATOLOGY

2007 4 WEEK THERAPY WITH THE NON-NUCLEOSIDIC POLYMERASE INHIBITOR BI207127 IN COMBINATION WITH PEGINTERFERON-ALFA2A AND RIBAVIRIN IN TREATMENT NAIVE AND TREATMENT EXPERIENCED CHRONIC HCV GT1 PATIENTS

(2010) D. Larrey et al.   JOURNAL OF HEPATOLOGY

2010 Q2WEEK CONTROLLED-RELEASE-INTERFERON-ALPHA2B + RIBAVRIN REDUCES FLU-LIKE SYMPTOMS >50% AND PROVIDES EQUIVALENT EFFICACY IN COMPARISON TO WEEKLY PEGYLATED-INTERFERON-ALPHA2B + RIBAVIRIN IN TREATMENT-NAIVE-GENOTYPE-1-CHRONIC-HEPATITIS-C: RESULTS FROM EMPOWER, A RANDOMIZED-OPEN-LABEL-12-WEEK-COMPARISON IN 133 PATIENTS

(2010) W.A. Long et al.   JOURNAL OF HEPATOLOGY

2008 DOSE-RANGING, THREE-DAY MONOTHERAPY STUDY OF THE HCV NS3 PROTEASE INHIBITOR GS-9256

(2010) E.J. Lawitz et al.   JOURNAL OF HEPATOLOGY

251 GENOTYPIC AND PHENOTYPIC CHARACTERIZATION OF GENOTYPE 2/3 HCV VARIANTS IN PATIENTS TREATED WITH TELAPREVIR ALONE OR IN COMBINATION WITH PEGINTERFERON ALFA-2A/RIBAVIRIN IN STUDY C209

(2010) S. De Meyer et al.   JOURNAL OF HEPATOLOGY

35 GENOTYPIC CHARACTERISATION OF FILIBUVIR (PF-00868554) RESISTANCE IN PATIENTS RECEIVING FOUR WEEKS CO-ADMINISTRATION OF FILIBUVIR WITH PEGIFN/RBV (12 WEEK ANALYSIS)

(2010) J. Mori et al.   JOURNAL OF HEPATOLOGY

749 EARLY ON-TREATMENT RESPONSES DURING PEGYLATED IFN PLUS RIBAVIRIN ARE INCREASED FOLLOWING 13 DAYS OF COMBINATION NUCLEOSIDE POLYMERASE (RG7128) AND PROTEASE (RG7227) INHIBITOR THERAPY (INFORM-1)

(2010) E. Gane et al.   JOURNAL OF HEPATOLOGY

31 SAFETY AND ANTIVIRAL ACTIVITY OF THE HCV NON-NUCLEOSIDE POLYMERASE INHIBITOR VX-222 IN TREATMENT-NAIVE GENOTYPE 1 HCV-INFECTED PATIENTS

(2010) M. Rodriguez-Torres et al.   JOURNAL OF HEPATOLOGY

2009 SAFETY AND ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH PEGYLATED INTERFERON α2A PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 CHRONIC HCV PATIENTS

(2010) E. Lawitz et al.   JOURNAL OF HEPATOLOGY

2013 ANTIVIRAL ACTIVITY, PHARMACOKINETICS AND SAFETY OF IDX184 IN COMBINATION WITH PEGYLATED INTERFERON (PEGIFN) AND RIBAVIRIN (RBV) IN TREATMENT-NAIVE HCV GENOTYPE 1-INFECTED SUBJECTS

(2010) J. Lalezari et al.   JOURNAL OF HEPATOLOGY

2016 LONG-TERM OUTCOMES FOLLOWING COMBINATION TREATMENT WITH BOCEPREVIR PLUS PEG-INTRON/RIBAVIRIN (P/R) IN PATIENTS WITH CHRONIC HEPATITIS C, GENOTYPE 1 (CHC-G1)

(2010) J.M. Vierling et al.   JOURNAL OF HEPATOLOGY

Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients

(2010) Christoph Sarrazin et al.   JOURNAL OF HEPATOLOGY

Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms

(2010) Wolf Peter Hofmann et al.   LIVER INTERNATIONAL

An Open Pilot Study Exploring the Efficacy of Fluvastatin, Pegylated Interferon and Ribavirin in Patients with Hepatitis C Virus Genotype 1b in High Viral Loads

(2009) Hitomi Sezaki et al.   INTERVIROLOGY

1055 ANTIVIRAL ACTIVITY OF ANA598, A POTENT NON- NUCLEOSIDE POLYMERASE INHIBITOR, IN CHRONIC HEPATITIS C PATIENTS

(2009) E. Lawitz et al.   JOURNAL OF HEPATOLOGY

647 TREATMENT OF HEPATITIS C WITH THE IMMUNE- STIMULATING DIPEPTIDE SCV-07

(2009) C. Tuthill et al.   JOURNAL OF HEPATOLOGY

1054 SAFETY, PHARMACOKINETICS AND ANTIVIRAL EFFECT OF BI 207127, A NOVEL HCV RNA POLYMERASE INHIBITOR, AFTER 5 DAYS ORAL TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C

(2009) D. Larrey et al.   JOURNAL OF HEPATOLOGY

86 SAFETY AND ANTIVIRAL ACTIVITY OF SCH 900518 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH PEGINTERFERON ALFA-2B TO NAIVE AND TREATMENT-EXPERIENCED HCV-1 INFECTED PATIENTS

(2009) H. Reesink et al.   JOURNAL OF HEPATOLOGY

Evaluation of VCH-759 monotherapy in hepatitis C infection

(2009) Curtis Cooper et al.   JOURNAL OF HEPATOLOGY

Safety and efficacy of viramidine versus ribavirin in ViSER2: Randomized, double-blind study in therapy-naive hepatitis C patients

(2009) Patrick Marcellin et al.   JOURNAL OF HEPATOLOGY

Hepatitis C Virus NS2 Protein Contributes to Virus Particle Assembly via Opposing Epistatic Interactions with the E1-E2 Glycoprotein and NS3-NS4A Enzyme Complexes

(2009) T. Phan et al.   JOURNAL OF VIROLOGY

Pioglitazone improves virological response to peginterferon α-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance

(2009) Mahmoud Khattab et al.   LIVER INTERNATIONAL

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

(2009) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Antiviral Activity of Albinterferon Alfa-2b in Prior Interferon Nonresponders With Chronic Hepatitis C

(2008) David R. Nelson et al.   Clinical Gastroenterology and Hepatology

Silibinin Is a Potent Antiviral Agent in Patients With Chronic Hepatitis C Not Responding to Pegylated Interferon/Ribavirin Therapy

(2008) Peter Ferenci et al.   GASTROENTEROLOGY

R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin

(2008) Paul J. Pockros et al.   HEPATOLOGY

Robust antiviral activity of R1626, a novel nucleoside analog: A randomized, placebo-controlled study in patients with chronic hepatitis C

(2008) Stuart K. Roberts et al.   HEPATOLOGY

143 EFFICACY AND SAFETY OF INCREASING DOSES OF THE CYCLOPHILIN INHIBITOR DEBIO 025 IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2A IN TREATMENT NAIVE CHRONIC HCV PATIENTS

(2008) R. Flisiak et al.   JOURNAL OF HEPATOLOGY